Novel findings of the current study were the significant risk reduction with soy isoflavones for recurrence in estrogen receptor–positive survivors and the significant associations between ENL and breast cancer–specific mortality as well as all-cause mortality for women with node-negative disease. This evidence concerns the gene ESR1 and breast carcinoma.